SCHEMBL25510876

SCHEMBL25510876

CCCN(CCC)c1nc(C(F)(F)F)ccc1CC

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPV1 Q8NER1 9/20 0.47
CYP3A4 P08684 1/20 0.37
TSHR P16473 1/20 0.37
MAPK1 P28482 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
CRHR1 P34998 2/20 0.35
AR P10275 1/20 0.33
ALOX15 P16050 1/20 0.33
CREBBP Q92793 1/20 0.33
MAPT P10636 1/20 0.33
TUBB4A P04350 1/20 0.33
TUBB P07437 1/20 0.33
TUBA3C P0DPH7 1/20 0.33
TUBA1B P68363 1/20 0.33
TUBA4A P68366 1/20 0.33
TUBB4B P68371 1/20 0.33
TUBB3 Q13509 1/20 0.33
TUBB2A Q13885 1/20 0.33
TUBB8 Q3ZCM7 1/20 0.33
TUBA3E Q6PEY2 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2527404 0.88 TRPV1 (0.44) TRPV1CYP3A4TSHRMAPK1TDP1
SCHEMBL25510875 0.87 TRPV1 (0.44) TRPV1TSHRALOX15CREBBPTUBB4A
SCHEMBL2532608 0.77 AR (0.47) TRPV1MAPK1TDP1ARMAPT
SCHEMBL12167500 0.76 TRPV1 (0.44) TRPV1CRHR1MAPT
SCHEMBL2525069 0.74 TRPV1 (0.41) TRPV1TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL2527456 0.73 TRPV1 (0.41) TRPV1CRHR1ALOX15CREBBPMAPT
SCHEMBL5265318 0.72 LMNA (0.40) TRPV1CYP3A4
SCHEMBL13039529 0.70 GABRA1 (0.39) TRPV1
SCHEMBL12266190 0.70 TRPV1 (0.40) TRPV1
SCHEMBL16647833 0.70 TKT (0.46)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230147428-A1 BENZIMIDAZOLONE-BASED CINNAMAMIDE DERIVATIVE AS TRPV1 ANTAGONIST AND PHARMACEUTICAL COMPOSITION FOR TREATMENT OR PREVENTION OF PAIN CONTAINING SAME AS ACTIVE INGREDIENT JMACKEM CO., LTD (KR) 2023-05-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230147428-A1 BENZIMIDAZOLONE-BASED CINNAMAMIDE DERIVATIVE AS TRPV1 ANTAGONIST AND PHARMACEUTICAL COMPOSITION FOR TREATMENT OR PREVENTION OF PAIN CONTAINING SAME AS ACTIVE INGREDIENT TRPV1, TRPA1, TRPV5 TRPV1 1/4885CYP3A4 1361/4885TSHR 4190/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.